A2A 01
Alternative Names: A2A-01; A2A-I-01; TYK2 inhibitor therapeutics - A2A Pharmaceuticals; Tyrosine kinase 2 inhibitor - A2A PharmaceuticalsLatest Information Update: 08 Dec 2021
At a glance
- Originator A2A Pharmaceuticals
- Class Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 26 Nov 2021 Early research in Autoimmune disorders in USA (unspecified route) (A2A Pharmaceuticals pipeline, November 2021)
- 26 Nov 2021 A2A Pharmaceuticals announces intention to submit IND to US FDA for Autoimmune disorders in 2023 (A2A Pharmaceuticals pipeline, November 2021)